Amneal Pharmaceuticals Inc Financials

AMRX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Amneal Pharmaceuticals Inc (AMRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Revenue

$2.8B

YoY+33.4%

5Y CAGR+22.0%

Amneal Pharmaceuticals Inc generated $2.8B in revenue in fiscal year 2024. This represents an increase of 33.4% from the prior year.

EBITDA

$490.1M

YoY+25.4%

5Y CAGR+6.4%

Amneal Pharmaceuticals Inc's EBITDA was $490.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.4% from the prior year.

Free Cash Flow

$243.2M

YoY+25.3%

5Y CAGR+11.8%

Amneal Pharmaceuticals Inc generated $243.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 25.3% from the prior year.

Net Income

-$73.9M

YoY-661.2%

Amneal Pharmaceuticals Inc reported -$73.9M in net income in fiscal year 2024. This represents a decrease of 661.2% from the prior year.

EPS (Diluted)

$-0.38

YoY-642.9%

Amneal Pharmaceuticals Inc earned $-0.38 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 642.9% from the prior year.

Cash & Debt

$110.6M

YoY-55.4%

5Y CAGR+8.3%

Amneal Pharmaceuticals Inc held $110.6M in cash against $2.2B in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

310M

5Y CAGR+1153.9%

Amneal Pharmaceuticals Inc had 310M shares outstanding in fiscal year 2024.

Gross Margin

36.5%

YoY-0.2pp

5Y CAGR-14.4pp

Amneal Pharmaceuticals Inc's gross margin was 36.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 0.2 percentage points from the prior year.

Operating Margin

8.9%

YoY+1.6pp

5Y CAGR-14.8pp

Amneal Pharmaceuticals Inc's operating margin was 8.9% in fiscal year 2024, reflecting core business profitability. This is up 1.6 percentage points from the prior year.

Net Margin

-2.6%

YoY-3.3pp

5Y CAGR-2.6pp

Amneal Pharmaceuticals Inc's net profit margin was -2.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 3.3 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$190.7M

YoY-5.5%

5Y CAGR+2.2%

Amneal Pharmaceuticals Inc invested $190.7M in research and development in fiscal year 2024. This represents a decrease of 5.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$51.9M

YoY+8.8%

5Y CAGR-11.3%

Amneal Pharmaceuticals Inc invested $51.9M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 8.8% from the prior year.

AMRX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$2.8B+33.4%	$2.1B+5.1%	$2.0B+22.5%	$1.6B-2.2%	$1.7B+60.9%	$1.0B
Cost of Revenue	$1.8B+33.9%	$1.3B-0.4%	$1.3B+15.9%	$1.1B+22.2%	$938.8M+85.0%	$507.5M
Gross Profit	$1.0B+32.7%	$769.0M+22.4%	$628.4M+78.0%	$353.0M-50.7%	$716.4M+36.2%	$526.2M
R&D Expenses	$190.7M-5.5%	$201.8M+12.2%	$179.9M-4.3%	$188.0M-3.2%	$194.2M+13.3%	$171.4M
SG&A Expenses	$476.4M+30.4%	$365.5M+11.9%	$326.7M+12.8%	$289.6M+27.1%	$227.8M+108.9%	$109.0M
Operating Income	$249.3M+63.3%	$152.7M+67.5%	$91.2M+136.7%	-$248.7M-1164.1%	-$19.7M-108.0%	$245.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$18.9M+68.5%	$11.2M+110.7%	-$104.4M-127.2%	$383.3M+27114.2%	-$1.4M-171.0%	$2.0M
Net Income	-$73.9M-661.2%	$13.2M-80.6%	$67.8M+111.2%	-$603.6M-2957.0%	-$19.7M	$0
EPS (Diluted)	$-0.38-642.9%	$0.07-88.5%	$0.61+122.3%	$-2.74-1612.5%	$-0.16	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$784.5M+8.3%	$724.5M+4.2%	$695.4M+12.7%	$617.0M-0.5%	$620.0M+3.5%	$599.0M+7.4%	$557.5M-8.6%	$609.8M
Cost of Revenue	$510.5M+16.5%	$438.3M-0.3%	$439.5M+2.9%	$427.2M+10.2%	$387.5M+2.2%	$379.0M-0.1%	$379.4M-3.8%	$394.4M
Gross Profit	$274.0M-4.3%	$286.3M+11.9%	$255.9M+34.8%	$189.8M-18.4%	$232.5M+5.7%	$220.0M+23.5%	$178.2M-17.3%	$215.4M
R&D Expenses	$63.4M+32.1%	$48.0M+19.8%	$40.0M-13.1%	$46.1M+11.4%	$41.4M+9.5%	$37.8M-2.3%	$38.7M-7.7%	$41.9M
SG&A Expenses	$137.8M+10.9%	$124.3M+5.1%	$118.3M+8.5%	$109.0M-3.5%	$113.0M+7.0%	$105.6M+3.4%	$102.1M-0.1%	$102.2M
Operating Income	$70.3M-36.8%	$111.4M+11.0%	$100.3M+607.0%	$14.2M-81.2%	$75.6M-5.5%	$80.1M+132.5%	$34.4M-4.4%	$36.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$23.4M-245.1%	$16.1M+25.1%	$12.9M+30.2%	$9.9M+576.1%	-$2.1M-8926.1%	-$23K-103.4%	$668K+137.2%	-$1.8M
Net Income	$2.4M-89.4%	$22.4M+83.8%	$12.2M+119.2%	-$63.4M-754.6%	$9.7M-18.8%	$11.9M+271.6%	-$6.9M-284.2%	$3.8M
EPS (Diluted)	$0.01-85.7%	$0.07+75.0%	$0.04+107.0%	$-0.57-1050.0%	$0.06-25.0%	$0.08+260.0%	$-0.05-66.7%	$-0.03

AMRX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$3.5B-11.1%	$3.9B-1.7%	$4.0B+9.3%	$3.7B-15.8%	$4.4B+224.4%	$1.3B
Current Assets	$1.6B+4.5%	$1.5B-2.0%	$1.6B+28.2%	$1.2B-5.9%	$1.3B+66.7%	$771.9M
Cash & Equivalents	$110.6M-55.4%	$247.8M-27.4%	$341.4M+125.8%	$151.2M-29.1%	$213.4M+187.7%	$74.2M
Inventory	$612.5M+25.1%	$489.4M-0.3%	$490.6M+28.8%	$381.1M-16.7%	$457.2M+61.0%	$284.0M
Accounts Receivable	$741.8M+12.0%	$662.6M+3.7%	$638.9M+5.7%	$604.4M+25.5%	$481.5M+37.0%	$351.4M
Goodwill	$597.4M+0.7%	$593.0M+13.4%	$522.8M+24.6%	$419.5M-1.6%	$426.2M+1511.8%	$26.4M
Total Liabilities	$3.6B+1.1%	$3.6B-2.4%	$3.7B+10.3%	$3.3B-4.0%	$3.5B+157.6%	$1.3B
Current Liabilities	$1.1B+66.8%	$677.2M+0.1%	$676.9M+23.0%	$550.4M-0.6%	$553.9M+86.6%	$296.9M
Long-Term Debt	$2.2B-19.3%	$2.7B-2.0%	$2.7B+4.8%	$2.6B-0.8%	$2.6B+94.1%	$1.4B
Total Equity	-$109.3M-129.8%	$367.0M+6.4%	$344.9M-0.5%	$346.8M-61.3%	$896.4M	$0
Retained Earnings	-$607.1M-119.8%	-$276.2M+3.7%	-$286.8M+24.1%	-$377.9M-1706.3%	-$20.9M+94.5%	-$382.8M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$3.6B+5.2%	$3.4B+1.7%	$3.4B-3.1%	$3.5B-5.8%	$3.7B-0.4%	$3.7B+2.0%	$3.6B-4.5%	$3.8B
Current Assets	$1.8B+16.0%	$1.6B+4.9%	$1.5B+9.6%	$1.4B-5.4%	$1.5B+2.4%	$1.4B+8.8%	$1.3B-7.4%	$1.4B
Cash & Equivalents	$201.2M+181.3%	$71.5M+20.9%	$59.2M-35.3%	$91.5M+5.3%	$86.9M-20.5%	$109.3M-24.5%	$144.7M+457.0%	$26.0M
Inventory	$614.5M+0.9%	$609.0M+1.3%	$601.4M+3.4%	$581.4M+0.9%	$576.5M+4.7%	$550.6M+4.1%	$529.0M-0.3%	$530.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$545.8M-26.4%	$741.8M
Goodwill	$595.9M-0.2%	$597.4M0.0%	$597.5M-0.2%	$598.6M0.0%	$598.6M-0.1%	$599.2M0.0%	$599.2M+0.1%	$598.9M
Total Liabilities	$3.7B+4.9%	$3.5B+1.1%	$3.5B+1.3%	$3.5B-2.3%	$3.5B-0.5%	$3.6B+1.7%	$3.5B-3.4%	$3.6B
Current Liabilities	$862.1M-22.1%	$1.1B+2.9%	$1.1B+27.1%	$846.6M+11.3%	$760.6M-2.2%	$777.4M+10.5%	$703.7M-6.5%	$752.8M
Long-Term Debt	$2.6B+19.6%	$2.1B-0.4%	$2.2B-9.7%	$2.4B-6.1%	$2.5B-0.3%	$2.5B-0.5%	$2.6B-1.2%	$2.6B
Total Equity	-$109.5M+2.7%	-$112.5M+14.7%	-$132.0M-759.6%	$20.0M-87.0%	$154.2M+2.3%	$150.8M+12.0%	$134.7M-26.8%	$184.0M
Retained Earnings	-$570.1M+0.4%	-$572.5M+3.8%	-$594.9M-21.4%	-$490.2M-25.2%	-$391.5M+2.4%	-$401.2M+2.9%	-$413.1M-1.7%	-$406.2M

AMRX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$295.1M+22.0%	$241.8M-36.2%	$379.0M+22128.8%	$1.7M-99.3%	$250.2M+6.9%	$234.2M
Capital Expenditures	$51.9M+8.8%	$47.7M-15.4%	$56.4M+19.6%	$47.2M-43.2%	$83.1M-12.3%	$94.8M
Free Cash Flow	$243.2M+25.3%	$194.1M-39.8%	$322.6M+809.3%	-$45.5M-127.2%	$167.1M+19.9%	$139.4M
Investing Cash Flow	-$63.0M+67.6%	-$194.2M+38.8%	-$317.5M-1521.8%	-$19.6M+95.1%	-$396.4M-302.2%	-$98.6M
Financing Cash Flow	-$211.8M-53.3%	-$138.1M-204.8%	$131.8M+387.6%	-$45.8M-115.9%	$287.7M+402.8%	-$95.0M
Dividends Paid	N/A	N/A	$0	$0-100.0%	$183.0M-51.2%	$375.3M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	N/A	N/A	$7.4M	N/A	N/A	N/A	$139.7M	N/A
Capital Expenditures	N/A	N/A	$13.2M	N/A	N/A	N/A	$9.7M	N/A
Free Cash Flow	N/A	N/A	-$5.8M	N/A	N/A	N/A	$130.0M	N/A
Investing Cash Flow	N/A	N/A	-$17.8M	N/A	N/A	N/A	-$11.7M	N/A
Financing Cash Flow	N/A	N/A	-$39.2M	N/A	N/A	N/A	-$12.9M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AMRX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	36.5%-0.2pp	36.7%+5.2pp	31.5%+9.8pp	21.7%-21.4pp	43.1%-7.8pp	50.9%
Operating Margin	8.9%+1.6pp	7.3%+2.7pp	4.6%+19.9pp	-15.3%-14.1pp	-1.2%-24.9pp	23.7%
Net Margin	-2.6%-3.3pp	0.6%-2.8pp	3.4%+40.5pp	-37.1%-35.9pp	-1.2%-1.2pp	0.0%
Return on Equity	N/A	3.6%-16.1pp	19.7%	N/A	N/A	N/A
Return on Assets	-2.1%-2.4pp	0.3%-1.4pp	1.7%+18.1pp	-16.5%-16.0pp	-0.4%-0.4pp	0.0%
Current Ratio	1.41-0.8	2.24-0.0	2.29+0.1	2.20-0.1	2.32-0.3	2.60
Debt-to-Equity	-19.78-27.1	7.30-0.6	7.93+0.4	7.52+4.6	2.93	N/A
FCF Margin	8.7%-0.6pp	9.3%-6.9pp	16.2%+19.0pp	-2.8%-12.8pp	10.1%-3.4pp	13.5%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	34.9%-4.6pp	39.5%+2.7pp	36.8%+6.0pp	30.8%-6.7pp	37.5%+0.8pp	36.7%+4.8pp	32.0%-3.4pp	35.3%
Operating Margin	9.0%-6.4pp	15.4%+0.9pp	14.4%+12.1pp	2.3%-9.9pp	12.2%-1.2pp	13.4%+7.2pp	6.2%+0.3pp	5.9%
Net Margin	0.3%-2.8pp	3.1%+1.3pp	1.8%+12.0pp	-10.3%-11.8pp	1.6%-0.4pp	2.0%+3.2pp	-1.3%-1.9pp	0.6%
Return on Equity	N/A	N/A	N/A	N/A	6.3%-1.6pp	7.9%	N/A	2.1%
Return on Assets	0.1%-0.6pp	0.7%+0.3pp	0.4%+2.2pp	-1.8%-2.1pp	0.3%-0.1pp	0.3%+0.5pp	-0.2%-0.3pp	0.1%
Current Ratio	2.13+0.7	1.43+0.0	1.40-0.2	1.63-0.3	1.91+0.1	1.83-0.0	1.86-0.0	1.88
Debt-to-Equity	-23.45-4.4	-19.07-2.8	-16.32-135.6	119.23+102.8	16.48-0.4	16.91-2.1	19.02+4.9	14.09
FCF Margin	N/A	N/A	-0.8%	N/A	N/A	N/A	23.3%	N/A

Note: Shareholder equity is negative (-$109.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Financial Health Signals

Financial Profile 56/100

Profitability

Growth

100

Leverage

N/A

Liquidity

Cash Flow

Returns

N/A

Based on FY2024 annual data. Scores normalized against common benchmarks.

Altman Z-Score Distress

1.71

Bankruptcy risk indicator. Above 2.99 = safe, below 1.81 = distress.

Piotroski F-Score Neutral

4/9

Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.

Earnings Quality Mixed

-3.99x

Operating cash flow vs net income. Above 1.0x = cash-backed earnings.

Similar Companies

Prestige Consmr Healthcare Inc PBH

$3.2B

Indivior Pharmaceuticals Inc INDV

$4.2B

Perrigo Co Plc PRGO

$2.0B

Hutchmed (China) Limited HCM

$2.5B

Bausch Health Companies Inc BHC

$2.2B

Frequently Asked Questions

What is Amneal Pharmaceuticals Inc's annual revenue?

Amneal Pharmaceuticals Inc (AMRX) reported $2.8B in total revenue for fiscal year 2024. This represents a 33.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Amneal Pharmaceuticals Inc's revenue growing?

Amneal Pharmaceuticals Inc (AMRX) revenue grew by 33.4% year-over-year, from $2.1B to $2.8B in fiscal year 2024.

Is Amneal Pharmaceuticals Inc profitable?

No, Amneal Pharmaceuticals Inc (AMRX) reported a net income of -$73.9M in fiscal year 2024, with a net profit margin of -2.6%.

What is Amneal Pharmaceuticals Inc's earnings per share (EPS)?

Amneal Pharmaceuticals Inc (AMRX) reported diluted earnings per share of $-0.38 for fiscal year 2024. This represents a -642.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Amneal Pharmaceuticals Inc's EBITDA?

Amneal Pharmaceuticals Inc (AMRX) had EBITDA of $490.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Amneal Pharmaceuticals Inc have?

As of fiscal year 2024, Amneal Pharmaceuticals Inc (AMRX) had $110.6M in cash and equivalents against $2.2B in long-term debt.

What is Amneal Pharmaceuticals Inc's gross margin?

Amneal Pharmaceuticals Inc (AMRX) had a gross margin of 36.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Amneal Pharmaceuticals Inc's operating margin?

Amneal Pharmaceuticals Inc (AMRX) had an operating margin of 8.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Amneal Pharmaceuticals Inc's net profit margin?

Amneal Pharmaceuticals Inc (AMRX) had a net profit margin of -2.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Amneal Pharmaceuticals Inc's free cash flow?

Amneal Pharmaceuticals Inc (AMRX) generated $243.2M in free cash flow during fiscal year 2024. This represents a 25.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Amneal Pharmaceuticals Inc's operating cash flow?

Amneal Pharmaceuticals Inc (AMRX) generated $295.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Amneal Pharmaceuticals Inc's total assets?

Amneal Pharmaceuticals Inc (AMRX) had $3.5B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Amneal Pharmaceuticals Inc's capital expenditures?

Amneal Pharmaceuticals Inc (AMRX) invested $51.9M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Amneal Pharmaceuticals Inc spend on research and development?

Amneal Pharmaceuticals Inc (AMRX) invested $190.7M in research and development during fiscal year 2024.

How many shares does Amneal Pharmaceuticals Inc have outstanding?

Amneal Pharmaceuticals Inc (AMRX) had 310M shares outstanding as of fiscal year 2024.

What is Amneal Pharmaceuticals Inc's current ratio?

Amneal Pharmaceuticals Inc (AMRX) had a current ratio of 1.41 as of fiscal year 2024, which is considered adequate.

What is Amneal Pharmaceuticals Inc's debt-to-equity ratio?

Amneal Pharmaceuticals Inc (AMRX) had a debt-to-equity ratio of -19.78 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Amneal Pharmaceuticals Inc's return on assets (ROA)?

Amneal Pharmaceuticals Inc (AMRX) had a return on assets of -2.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Why is Amneal Pharmaceuticals Inc's debt-to-equity ratio negative or unusual?

Amneal Pharmaceuticals Inc (AMRX) has negative shareholder equity of -$109.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Amneal Pharmaceuticals Inc's Altman Z-Score?

Amneal Pharmaceuticals Inc (AMRX) has an Altman Z-Score of 1.71, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress.

What is Amneal Pharmaceuticals Inc's Piotroski F-Score?

Amneal Pharmaceuticals Inc (AMRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Are Amneal Pharmaceuticals Inc's earnings high quality?

Amneal Pharmaceuticals Inc (AMRX) has an earnings quality ratio of -3.99x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

How financially healthy is Amneal Pharmaceuticals Inc?

Amneal Pharmaceuticals Inc (AMRX) scores 56 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.